Glomerulonephritis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Glomerulonephritis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H2 2014', provides an overview of the Glomerulonephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glomerulonephritis Overview 6
Therapeutics Development 7
Pipeline Products for Glomerulonephritis - Overview 7
Pipeline Products for Glomerulonephritis - Comparative Analysis 8
Glomerulonephritis - Therapeutics under Development by Companies 9
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 10
Glomerulonephritis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Glomerulonephritis - Products under Development by Companies 13
Glomerulonephritis - Products under Investigation by Universities/Institutes 14
Glomerulonephritis - Companies Involved in Therapeutics Development 15
Cyclacel Pharmaceuticals, Inc. 15
Toray Industries, Inc. 16
Hansa Medical AB 17
Pharmalink AB 18
Avexxin AS 19
FibroStatin SL 20
Glomerulonephritis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Drug Profiles 29
budesonide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CYC-065 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Endoglycosidase of Streptococcus pyogenes - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AVX-235 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Peptide to Inhibit ETA and ETB for Rapidly Progressive Glomerulonephritis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GPBP Inhibitors - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Glomerulonephritis - Recent Pipeline Updates 38
Glomerulonephritis - Dormant Projects 40
Glomerulonephritis - Product Development Milestones 41
Featured News & Press Releases 41
Feb 19, 2014: Regulus Advances Orphan Disease Portfolio with Nomination of RG-012 as Clinical Development Candidate for the Treatment of Alport Syndrome 41
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 42
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 43
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 43
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 44
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Glomerulonephritis, H2 2014 7
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Glomerulonephritis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 15
Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2014 16
Glomerulonephritis - Pipeline by Hansa Medical AB, H2 2014 17
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2014 18
Glomerulonephritis - Pipeline by Avexxin AS, H2 2014 19
Glomerulonephritis - Pipeline by FibroStatin SL, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Glomerulonephritis Therapeutics - Recent Pipeline Updates, H2 2014 38
Glomerulonephritis - Dormant Projects, H2 2014 40